LS
Lawrence Steinman
Director

Lawrence Steinman insider trades: Pasithea Therapeutics (KTTA) stock buys and sales

Director, Pasithea Therapeutics Last trade Nov 28, 2025 32 Form 4 filings
$0
Sold, last 12 months
0 sales
$100K
Bought, last 12 months
1 buy
9
Open-market trades
since 2021
4
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Lawrence reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 28, 2025KTTA↑ Buy$100K
Dec 19, 2023BCAB↑ Buy$41K
Jun 2, 2023KTTA↑ Buy$13K
Jun 1, 2023ATNF↑ Buy$22K
Dec 9, 2021ATNF↑ Buy$21K
Nov 2, 2021BCAB↓ Sell$14K
Sep 15, 2021BCAB↓ Sell$17K
Aug 16, 2021BCAB↓ Sell$18K
Jul 15, 2021BCAB↓ Sell$17K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other KTTA insiders

Open-market trades in the last 12 months

About Lawrence Steinman's insider trades

Lawrence Steinman is a director at Pasithea Therapeutics (KTTA). Since Jul 15, 2021, Lawrence has reported 5 open-market purchases worth $197K and 4 sales worth $66K on SEC Form 4. In the last 12 months: 1 buy ($100K).

Their filings also include grants and awards (23 filings), other transactions (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KTTA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.